TAVR Market: Next-Generation Devices Seek To Optimize Outcomes
Executive Summary
The market opportunity for TAVR is significant, with 2013 sales totaling $303.4 million in the US and $765 million outside the US, and those numbers are expected to grow to an estimated $1.29 billion and $1.63 billion, respectively, by 2018. Edwards and Medtronic dominate the worldwide market at present, but other companies are expected to make inroads with next-generation devices designed to optimize outcomes.
You may also be interested in...
Stroke Prevention For TAVR – And, Perhaps, Beyond
Although TAVR-related stroke rates have been diminishing, it remains a devastating complication of the procedure. Two companies with devices to deflect or collect emboli are embarking on IDE trials that they hope will make cerebral embolic protection a standard of care in TAVR and perhaps other cardiac surgeries, as it already is in carotid artery stenting.
Stroke Prevention For TAVR – And, Perhaps, Beyond
Although TAVR-related stroke rates have been diminishing, it remains a devastating complication of the procedure. Two companies with devices to deflect or collect emboli are embarking on IDE trials that they hope will make cerebral embolic protection a standard of care in TAVR and perhaps other cardiac surgeries, as it already is in carotid artery stenting.
TAVR Market Shifting Into High Gear
Momentum is building in the burgeoning and rapidly evolving transcatheter aortic valve replacement (TAVR) market. With a growing body of clinical evidence, the potential for expanded indications in lower-risk patients, and more favorable reimbursement on the horizon, the TAVR market is shifting into high gear, with solid, double-digit growth ahead.